Urogen Pharma (NASDAQ:URGN) Given Average Rating of “Moderate Buy” by Analysts

Urogen Pharma (NASDAQ:URGN) has earned an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $33.2857.

Several research analysts have recently commented on URGN shares. D. Boral Capital reissued a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research report on Monday. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider directly owned 144,985 shares in the company, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after acquiring an additional 486 shares in the last quarter. State of Wyoming acquired a new stake in Urogen Pharma in the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. boosted its stake in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Osaic Holdings Inc. grew its position in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. Finally, Strs Ohio acquired a new position in Urogen Pharma during the 3rd quarter valued at approximately $76,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Urogen’s quarterly report beat EPS expectations (smaller loss than forecast), prompting an early gap?up in the shares as investors cheered the outcome. Read More.
• Positive Sentiment: D. Boral Capital assigned a “Buy” rating to URGN, which supports demand from investors looking for upside in the drug’s commercial rollout and can help short?term sentiment. Read More.
• Neutral Sentiment: Coverage discusses UroGen weighing the commercial success of ENVISION and an expanded loan to support its bladder cancer push — this could fund growth but also increases leverage and execution risk, so the market reaction is ambiguous. Read More.
• Negative Sentiment: HC Wainwright substantially lowered near?term EPS estimates: Q2 2026 to ($0.64) from ($0.42), Q3 2026 to ($0.42) from ($0.14), Q4 2026 to ($0.33) from $0.01, and cut FY2026 to ($1.99) from ($1.18). (They did slightly raise Q1 2026 to ($0.60) from ($0.63) and project FY2027 at $0.45.) These deeper downgrades to 2026 earnings signal weaker near?term profitability expectations and are the main negative catalyst weighing on the stock. Read More.

Urogen Pharma Stock Performance

Shares of URGN opened at $19.61 on Friday. The company has a 50 day moving average price of $20.94 and a 200-day moving average price of $20.86. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $30.00. The stock has a market capitalization of $954.61 million, a PE ratio of -6.13 and a beta of 1.34.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million. Equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.